Bristol’ schizophrenia drug nears approval, AbbVie hope to provide competition
19 Aug 2024 //
BIOPHARMADIVE
AbbVie Completes Acquisition of Cerevel Therapeutics
01 Aug 2024 //
PR NEWSWIRE
AbbVie to acquire Cerevel for $8.7 billion
07 Dec 2023 //
REUTERS